|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Current Assets: | ||||||||||||
| Cash | ||||||||||||
| Prepaid expenses | ||||||||||||
| Total Current Assets | ||||||||||||
| Investments held in trust | ||||||||||||
| Other assets | ||||||||||||
| Deferred offering costs | ||||||||||||
| Total Assets | ||||||||||||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||||||
| Current Liabilities: | ||||||||||||
| Accrued expenses and offering costs | ||||||||||||
| Accrued offering costs | ||||||||||||
| Promissory note payable - Sponsor | ||||||||||||
| Related party payable | ||||||||||||
| Note payable - Sponsor | ||||||||||||
| Convertible note payable - Sponsor | ||||||||||||
| Sponsor advance | ||||||||||||
| Total Current Liabilities | ||||||||||||
| Non-current Liabilities: | ||||||||||||
| Deferred underwriting fee payable | ||||||||||||
| Total Liabilities | ||||||||||||
| Class A ordinary shares subject to possible redemption; 2,236,713 shares at redemption value of $11.54 and $11.25 at June 30, 2026 and December 31, 2025, respectively | ||||||||||||
| Shareholders' Deficit: | ||||||||||||
| Ordinary shares | ||||||||||||
| Class A ordinary shares | ||||||||||||
| Class A ordinary shares not subject to possible redemption | ||||||||||||
| Total class A ordinary shares | ||||||||||||
| Class B ordinary shares | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total Shareholders' Deficit | ||||||||||||
| Total Liabilities and Shareholders' Deficit |
Loading...
